Medherant announces positive Phase I results for its first transdermal drug delivery patch
Coventry, UK, 5th November 2018 / Sciad Newswire / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.
The TEPI Patch was shown to be well tolerated by all subjects in a study of skin irritation and sensitisation. This marks the first clinical safety evaluation of Medherant’s novel adhesive, facilitating the development of the next generation of drug-in-adhesive patches.
In the second study, concentrations of ibuprofen in the blood following repeated application of the Ibuprofen TEPI Patch and a single oral dose of ibuprofen were compared. As expected, blood levels were significantly lower after application of the patch reflecting its design as a local delivery mechanism. Local application provides site-specific pain relief and a lower blood concentration will help minimise side effects.
Nigel Davis, CEO of Medherant, commented: “These positive Phase I results signify a major milestone in the ongoing development of our TEPI Patch drug delivery technology and demonstrate that our novel adhesive can be used safely. The successful completion of these trials is a testament to our team’s hard work and dedication. We look forward to taking the Ibuprofen TEPI Patch into Phase III clinical testing.”
The Company will be seeking Series A finance to support its Phase III Ibuprofen TEPI Patch study and to take its portfolio of TEPI Patch products, which includes a cannabinoid and patches for Alzheimer’s disease, into clinical development.
For further information, contact:
Nigel Davis, CEO
T: +44 (0)24 7632 3060
Media Relations, Sciad Communications
Juliette Craggs / Sophie Protheroe / Emma Pickup
T: +44 (0)20 7470 8801
Notes for Editors
Medherant Ltd is a developer of innovative transdermal drug delivery treatments for pain and CNS diseases. The Company was founded by Professor David Haddleton and the University of Warwick in 2015.
Medherant has built upon its founders’ world-leading expertise in bio-adhesives and polymer chemistry to create its unique patent protected TEPI Patch® drug delivery technology. TEPI Patch overcomes many of the limitations of patches currently on the market:
- TEPI Patch technology can be used with a wider range of drugs, including those that are not suitable for oral administration.
- The amount of drug that can be loaded into the patch is greater, enabling the development of more effective transdermal therapies.
- The TEPI Patch contains a novel adhesive which will provide a better patient experience as the patch sticks to the skin for longer, is less painful to remove, and does not leave a mark on the skin.
Medherant is developing products containing proven drugs that it intends to license prior to commercialisation. The Company’s first product is an ibuprofen patch.
Medherant also runs feasibility studies that give companies the opportunity to see the benefits of delivering their drugs using the TEPI Patch technology. Medherant seeks partnerships with companies wishing to extend the commercial life of their products or those that have drugs that cannot be delivered orally at sufficient dosage.
Medherant is backed by Mercia Technologies PLC, a national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential from the UK regions.
For more information, please see www.medherant.co.uk